Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.
University of Nebraska
University of Nebraska
Rush University Medical Center
Novartis
Novartis
Takeda
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
University of Maryland, Baltimore
University of Maryland, Baltimore
University of Chicago
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gruppo Italiano Malattie EMatologiche dell'Adulto
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Beth Israel Deaconess Medical Center
University of Chicago
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
FDA Office of Orphan Products Development
Teva Branded Pharmaceutical Products R&D, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of South Florida
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northside Hospital, Inc.
National Cancer Institute (NCI)